Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH-30643 in Advanced NSCLC With EGFR/HER2 Mutations
NCT06706076Phase 2Recruiting
- Sponsor
- BlossomHill Therapeutics
- Start
- Jan 2025
- Primary completion
- Jan 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 9
01
Overview
A Phase 2 trial of BH-30643 in non-small cell lung cancer (NSCLC), sponsored by BlossomHill Therapeutics. Started Jan 2025; status: recruiting.
02
Drugs
BH-30643
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06706076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706076.